Transforming growth factors (TGFs) are polypeptides that have in certain nontumorigenic cells an ability to reversibly induce features that resemble those of malignant transformation (1, 2) . There are two distinct types of TGFs, TGFa and TGF-0 (2, 3). TGF-a is related to epidermal growth factor (EGF) and shares the same cell surface receptors, while TGF-# is structurally and antigenically distinct (1, 2) . TGF-/3 has been molecularly cloned (4) . It is a homodimer with two disulfide-linked polypeptide chains of 12.5 kD (1, 4) . Cell surface receptors for TGF-,# are not related to the receptors of other known growth factors and are widely distributed in different cells and tissues (2, 5, 6) .
TGF-0 is present in a variety of cells including T cells, monocytes, and platelets (2, (7) (8) (9) . TGF-a also is known to stimulate production of fibronectin and collagen by dermal fibroblasts in vitro (8, 10, 11) . Roberts and coworkers (8) reported that the subcutaneous injection of TGF-0 in newborn mice induced a rapid fibrosis and accumulation of fibroblasts . This observation suggested to us that a function of TGF-0 might be to induce fibroblast chemotaxis . In this report we have observed that platelet-derived human TGF-/3 is a potent chemoattractant for fibroblasts in vitro .
Materials and Methods TGF-0 and EGF. TGF-0 was purified from homogenates of outdated human platelets by procedures developed in our laboratory and previously published in detail (1, 5, 7) . The preparations for TGF-0 used in this study were tested for purity by polypeptide analysis using silver staining of SDS polyacrylamide gels (1) . All preparations used contained only a 25-kD protein band on the gels which, after reduction with 2-ME, migrated as a single 12.5-kD band and were active at ng/ml concentrations in a soft agar colony formation assay using AKR-2B cells and growth inhibition assays using A549 indicator cells (1, 3) . Antibodies were raised in rabbits to one of these preparations of This work was supported in part by grants AM-16506 and AM-26034 from the National Institutes of Health (Bethesda, MD), CA-42572 from the National Cancer Institute, and research funds from the Veterans Administration . Address correspondence to Arnold E. Postlethwaite TGF-0 and specifically blocked the binding of TGF-0 to its receptor on AKR-2B cells . EGF was purified from male mouse submaxillary glands (5) .
Preparation of Anti-TGF-(3 Antibodies . Antibodies against homogeneously pure TGF-0 were raised in rabbits, and the IgG fraction was purified using a protein A-Sepharose column (Keski-Oja, J., R. M . Lyons, and H . L. Moses, manuscript in preparation) . Normal rabbit IgG was purified in a similar manner to be used as a control .
Fibroblast Chemotaxis . Fibroblast chemotaxis was measured in modified blind-well chemotaxis chambers equipped with porous (8 um) gelatin-treated polycarbonate filters as previously described (12) . All samples were tested in triplicate or quadruplicate, and where indicated activity was expressed as the mean number of fibroblasts per 200 :1 immersion fields (01F) ± SEM of the replicates .
Other Fibroblast Chemoattractants . Human plasma fibronectin, heat denatured type I calf skin collagen, and human platelet-derived growth factor (PDGF) were prepared as previously described (12) (13) (14) .
Incubation of Fibroblast Chemoattractants with Anti-TGF-/3 Antibodies. Purified IgG from control and TGF-0-immunized rabbits (14 and 140 wg/ml) were added (10 Pl) to separate 200-Al aliquots of PBS (Grand Island Biological Co., Grand Island, NY) containing fibronectin (600 ng), denatured type I collagen (6 mg), TGF-0 (3 pg), and PDGF (0 .3 pg) . All of the samples were incubated at 37' for 2 h with frequent mixing . Volumes were adjusted to 600 jul by addition of 390 wl serum-free Eagle's MEM (Grand Island Biological Co.) and were tested in triplicate for fibroblast chemotactic activity .
Reduction of TGF-0 by 2-ME . Two equal aliquots (1 .98 ml) of TGF-0 (500 ng/ml) were prepared, 2-ME (20 tel) was added to one aliquot while PBS (20 ,1) was added to the other . Both TGF-0 preparations were then kept at room temperature for 4 h. After extensive dialysis at 4°C against PBS, the preparations were tested for their chemotactic activity using the same assay at different doses .
Results
Chemotactic Property of TGF-/3. Purified human platelet-derived TGF-0 stimulated migration of fibroblasts in modified Boyden chemotaxis chambers (Fig.  1) . The dose-response curve was found to be bell-shaped, with maximal migration occurring at a concentration of 12.5 pg/ml in the experiment depicted in Fig . 1 . This same general dose-response curve was repeatedly observed with different preparations of TGF-a, with maximal migration always being observed at doses ranging from 5-50 pg/ml (data not shown).
Zigmond-Hirsch checkerboard analysis revealed that TGF-0 effected migration of fibroblasts only when present in higher concentration in the lower comparttnent of the chemotaxis chambers ( Table I ), suggesting that it induces chemotactic migration and not chemokinesis of fibroblasts (15) .
Denaturation of TGF-0 by reduction of its disulfide bonds with 2-ME resulted in a marked decrease in the ability of TGF-0 to act as a chemoattractant for fibroblasts (e.g., chemotactic activity of TGF-,0, 5 pg/ml, was diminished from 54 ± 5 fibroblasts per 20 OIF to a value of 14 ± 3 after reduction by 2-ME [migration to PBS control was 5 ± I]) .
EGF has recently been shown (8, 16) to be capable of inhibiting TGF-0-induced collagen synthesis by fibroblasts and to reverse TGF-(3-mediated growth inhibition of A549 human lung carcinoma cells. In light of these observations, we wanted to determine whether EGF might alter the chemotactic response of fibroblasts to TGF-#. To address this issue, fibroblasts used in a chemotaxis assay were incubated with different doses of EGF before and while they were present in the upper compartment of chemotaxis chambers whose lower compartments TGF-0 was tested in quadruplicate at the concentrations indicated for its ability to induce fibroblast migration in modified blind-well chemotaxis chambers (see Materials and Methods). The SE for each point on the graph were >15% of each mean value . Migration to PBS control was 5 ± 1 .
TABLE I Effect of Varying Concentration Gradients of TGF-0 on Fibroblast Migration
Different concentrations of TGF-,B were added to the upper and lower compartments of the chemotaxis chamber and the number of fibroblasts migrating to the lower surface of each filter was quantitated . Each value represents the mean of four replicates ± SEM . The values between the parallel lines were obtained when TGF-0 was present in a given chemotaxis chamber at the same concentration in the uppr and lower compartments .
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contained TGF-0 or denatured type I collagen . EGF did not alter the chemotactic response of fibroblasts to either chemoattractant (Table II) . These results indicate that the chemotactic responsiveness of fibroblasts to TGF-0 is probably not modulated by EGF. fibroblast chemoattractant but did not inhibit the chemotactic activity of human plasma fibronectin, human PDGF, or denatured type I calf skin collagen (Table  III) .
TGF-# purified from human platelets is a very potent chemoattractant for fibroblasts in vitro. Dissociation by reduction of chains of TGF-# causes a marked loss of its chemotactic potency, suggesting that the native structure of TGF-a is essential for its ability to induce fibroblast chemotaxis . Polyvalent antibodies raised in rabbits effectively block the chemotactic activity of TGF-,0 . These same antibodies have been demonstrated to block the growth inhibitory effects of TGF-# in fibroblasts (Keski-Oja, J., R. M. Lyons, and H. L. Moses, manuscript in preparation) and is probably exerting its effect in this study by preventing TGF-# from binding to receptors involved in the chemotactic response . The fact that the anti-TGF-0 antibodies did not inhibit the chemotactic activity of PDGF, fibronectin, or collagen further demonstrates specificity of the antibodies for TGF-0. A number of neoplastic and normal cells synthesize TGF-# (1, 2, 9, 11). The fact that TGF-# is produced by a variety of cells and can modulate several important fibroblast functions (i .e., chemotaxis, collagen, and fibronectin synthesis) may have far-reaching implications . For example, certain tumors (e.g., schirrous carcinoma of the breast and stomach and fibrosarcomas) are characterized by an excessive fibrotic reaction which could be caused by their releasing TGF-,0 (17) . During embryogenesis, TGF-0 may play a critical role in directing the migration of fibroblasts that synthesize the matrix scaffolding necessary for organogenesis. The release of TGF-fl from platelets, lymphocytes, and monocytes/macrophages at sites of immune and nonimmune tissue injury may play a critical role in effecting the migration of neighboring connective tissue fibroblasts . It could then act as a stimulus for fibroblasts to produce increased quantities of matrix components (collagens and fibronectin) .
Summary
Transforming growth factor ,Q (TGF-f3) is a potent chemoattractant in vitro for human dermal fibroblasts. Intact disulfide and perhaps the dimeric structure of TGF-a is essential for its ability to stimulate chemotactic migration of fibroblasts, since reduction with 2-ME results in a marked loss of its potency as a chemoattractant . Although epidermal growth factor (EGF) appears to be capable of modulating some effects of TGF-(l, it does not alter the chemotactic response of fibroblasts to TGF-,B. Specific polyvalent rabbit antibodies to homogenously pure TGF-0 block its chemotactic activity but has no effect on the other chemoattractants tested (platelet-derived growth factor, fibronectin, and denatured type I Collagen) . Since TGF-# is secreted by a variety of neoplastic and normal cells including platelets, monocytes/macrophages, and lymphocytes, it may play a critical role in vivo in embryogenesis, host response to tumors, and the repair response that follows damage to tissues by immune and nonimmune reactions.
